German Antitrust Authority Allows BASF-Siegfried Deal

Germany’s antitrust authority Bundeskartellamt has approved BASF’s plans to sell its custom synthesis business, part of the Nutrition & Health division, and parts of its current active pharmaceutical ingredients (APIs) business to Zofingen, Switzerland-based Siegfried Holding.

Following the divestment, which has an enterprise value of €270 million, BASF intends to focus on products for which it has a leading market position.

Siegfried will acquire APIs such as ephedrine, pseudoephedrine and caffeine, with annual sales of around €270 million, while BASF will retain its excipient portfolio and selected APIs, such as ibuprofen, omega-3 fatty acids and polyethylenglycol (PEG).

The Swiss company said it expects the transaction be finalized at the beginning of the fourth quarter.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Virtual Event

DIGITALIZATION IN THE CHEMICAL INDUSTRY

DIGITALIZATION IN THE CHEMICAL INDUSTRY

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.